Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
Postmus I, Johnson PC, Trompet S, de Craen AJ, Slagboom PE, Devlin JJ, Shiffman D, Sacks FM, Kearney PM, Stott DJ, Buckley BM, Sattar N, Ford I, Westendorp RG, Jukema JW. Postmus I, et al. Among authors: sacks fm. Atherosclerosis. 2014 Jul;235(1):58-64. doi: 10.1016/j.atherosclerosis.2014.04.009. Epub 2014 Apr 26. Atherosclerosis. 2014. PMID: 24816038 Clinical Trial.
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R. Hennekens CH, et al. Among authors: sacks fm. Arch Intern Med. 2004 Jan 12;164(1):40-4. doi: 10.1001/archinte.164.1.40. Arch Intern Med. 2004. PMID: 14718320
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AH, Zwinderman AH, Jukema JW, Sacks FM, Kastelein JJ, Kuivenhoven JA. de Grooth GJ, et al. Among authors: sacks fm. J Am Coll Cardiol. 2004 Mar 3;43(5):854-7. doi: 10.1016/j.jacc.2003.08.056. J Am Coll Cardiol. 2004. PMID: 14998629 Free article.
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ. Boekholdt SM, et al. Among authors: sacks fm. Circulation. 2005 Jan 25;111(3):278-87. doi: 10.1161/01.CIR.0000153341.46271.40. Epub 2005 Jan 17. Circulation. 2005. PMID: 15655129
Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke.
Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, Braunwald E, White TJ, Shaw PM, Dracopoli NC. Ranade K, et al. Among authors: sacks fm. Stroke. 2005 Nov;36(11):2346-50. doi: 10.1161/01.STR.0000185703.88944.7d. Epub 2005 Oct 20. Stroke. 2005. PMID: 16239632
The apolipoprotein story.
Sacks FM. Sacks FM. Atheroscler Suppl. 2006 Aug;7(4):23-7. doi: 10.1016/j.atherosclerosissup.2006.05.004. Epub 2006 Jul 5. Atheroscler Suppl. 2006. PMID: 16822722 Review.
407 results